We recently published 10 Stocks Lighting Up Market Ahead of Christmas. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of ...

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...

Shares of Agios Pharmaceuticals jumped nearly 16% on Wednesday after the U.S. Food and Drug Administration approved the ...

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or ...

The company received FDA approval for its leading drug, and investors were pleased with the update from management.

FDA approves Agios' Aqvesme for anemia in alpha and beta thalassemia, backed by Phase 3 data and a REMS safety program.

BofA raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $34 from $32 and keeps a Buy rating on the shares following FDA approval for mitapivat to make it the only drug approved in both ...

The biopharmaceutical company said Tuesday that Aqvesme is now the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.

Agios Pharmaceuticals shares surged after the FDA approved expanded use of its drug mitapivat for treating anemia in alpha- and beta-thalassemia patients.

Investing.com -- Agios Pharmaceuticals (NASDAQ:AGIO) stock fell 7% after the company announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on its ...

Agios Pharmaceuticals’ pivot from cancer to rare diseases culminated in the $1.8 billion sale of its oncology business. But the biotech still needs capital to support a product launch and additional ...

Dec 24 (Reuters) - Shares of Agios ‌Pharmaceuticals ​jumped nearly 12% premarket ‌on Wednesday after the U.S. Food ​and Drug Administration approved the expanded use of its drug ‍for the treatment of ...